The prevalence of antibodies to SARS-CoV-2 among blood donors in China

• DOI: 10.1101/2020.07.13.20153106
• Publication Date: 2020-07-14T18:19:37Z
• Authors: Le Chang; Wangheng Hou; Lei Zhao; Yali Zhang; Yanbin Wang; Linfeng Wu; Tingting Xu; Lilin Wang; Juan Wang; Jian Ma; Lan Wang; Junpeng Zhao; Jing Xu; Juan Dong; Ying Yan; Ru Yang; Yu Li; Fei Guo; Wenjuan Cheng; Yingying Su; Jinfeng Zeng; Wei Han; Tong Cheng; Jun Zhang; Quan Yuan; Ningshao Xia; Lunan Wang
• Keywords: Seroprevalence; Cross-sectional study; Pandemic

Abstract Objectives The prevalence of antibodies to SARS-CoV-2 among blood donors in China remains unknown. To reveal the missing information, we investigated seroprevalence cities Wuhan, Shenzhen, and Shijiazhuang China. Design Cross-sectional study Setting Three centers, located central, south north China, respectively, recruiting from January April 2020. Participants 38,144 healthy donated Shenzhen were enrolled, who all met criteria for donation during COVID-19 pandemic Main outcome measures Specific against including total antibody (TAb), IgG receptor-binding domain spike protein (IgG-RBD) nucleoprotein (IgG-N), IgM. Pseudotype lentivirus-based neutralization test was performed on TAb-positive samples. In addition, anonymous personal demographic gender, age, ethnicity, occupation educational level, type collected. Results A 519 samples 410 confirmed by tests. 2.29% (407/17,794, 95%CI: 2.08% 2.52%) 0.029% (2/6,810, 0.0081% 0.11%) 0.0074% (1/13,540, 0.0013% 0.042%) Shijiazhuang, respectively. earliest emergence seropositivity identified 20, 2020 Wuhan. weekly Wuhan’s changed dynamically 0.08% (95%CI: 0.02% 0.28%) 15 22 (before city lockdown), 3.08% 2.67% 3.55%) 23 7 (city quarantine period) 2.33% 2.06% 2.63%) 8 30 (after lockdown easing). Female older-age be independent risk factors Conclusions low, even Wuhan city. According our data, should not earlier than January, As most population remained uninfected early wave pandemic, effective public health are still certainly required block viral spread before a vaccine is widely available.